StemBioSys Acquires Majority Stake in Cartox

Axion BioSystems Acquires CytoSMART Technologies

March 21, 2022

Medical Devices

Axion BioSystems has acquired Netherlands-based CytoSMART Technologies, a developer of kinetic live-cell imaging systems and AI-powered image analysis tools. The acquisition expands Axion's product portfolio and capabilities in live-cell imaging to support research in stem cell biology, immuno-oncology, cell-based therapies, and drug discovery.

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

Medix Biochemica Group Acquires Bioresource Technology (BRT)

June 21, 2022

Biotechnology

Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.

AnaBios Acquires Cell Systems

April 4, 2023

Biotechnology

AnaBios Corporation has acquired Cell Systems, a Kirkland, Washington supplier of human primary cells and cell culture media, to expand its human tissue and cell portfolio and accelerate translational drug discovery. Financing for the transaction was provided by AnaBios' existing investors, including Ampersand Capital Partners; financial terms were not disclosed.

Cancer Genetics (Vyant Bio) Acquires StemoniX

March 31, 2021

Biotechnology

Cancer Genetics, Inc. completed a merger with StemoniX, Inc. and renamed the combined company Vyant Bio, Inc., with the new ticker VYNT on Nasdaq. StemoniX will operate as a wholly-owned subsidiary as the combined business integrates human iPSC-derived biology, software and preclinical capabilities to create a unified drug discovery platform.

STEMCELL Technologies Acquires Propagenix Inc.

January 19, 2024

Biotechnology

STEMCELL Technologies, Canada’s largest biotechnology company, acquired Propagenix Inc., a Gaithersburg, Maryland biotechnology firm focused on epithelial cell biology and its patented EpiX technology. The acquisition includes Propagenix’s assets, IP (including its Conditional Reprogramming license with Georgetown University) and existing business arrangements, enabling STEMCELL to develop EpiX-based products for clinical applications and expand its regenerative-medicine capabilities.